Abstract 1683P
Background
Patients (pts) with lung cancer (LC) are at high risk for hospitalization and mortality from COVID-19. Patients and physicians don`t feel safe to continue LC diagnosis and treatments. Modifications of LC management varied between countries. ESMO guidelines in the COVID-19 era were published promptly, during the COVID-19 epidemic in Europe aiming to guide all stakeholders in lung cancer.
Methods
A virtual meeting among LC experts from Belgium, Switzerland, Portugal, Slovenia, Norway, Croatia, Poland, Romania, Greece and Israel was held on April 27 to discuss the impact of the COVID-19 pandemic on the lung cancer care in each country. The discussion was based on the ESMO recommendations. Each participant described the SARS-CoV2 epidemic phase in country and filled a questionnaire based on the enforcement of each statement from the ESMO guidelines.
Results
All countries are in the community level SARS-CoV2 transmission. In 3 countries health care services exceeded their capacities. Four countries have implemented the ESMO guidelines without any modification (Switzerland, Norway, Israel and Croatia). High Level of recommendations in the outpatient and inpatient services were implemented in all countries with minor modifications. Intermediate level recommendations were implemented in 9 of 10 countries. Low priority level was implemented in 7 of 10 countries. Main modifications were: surgery for stage I NSCLC as a high priority, all non-curative surgical interventions postponed, differences in imaging priorities. In 5 of 10 countries local oncology societies issued recommendations mainly consistent with ESMO but medical oncologists also follow recommendations issued by the health ministry.
Conclusions
ESMO guidelines prioritizing LC management are implemented in all participating countries. High and intermediate level recommendations are implemented with minor modification regardless the phase of the pandemic. The differences among countries are not related to the phase of pandemic but mostly to the health system capacity and socioeconomic factors in each country.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Agbarya: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: MSD; Roche; AstraZeneca; BI; Pfizer; Takeda; Advisory/Consultancy: Novartis; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli Lilly; Honoraria (self), Speaker Bureau/Expert testimony: Merck Serono; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Sanofi. A. Addeo:Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self): AZD; Honoraria (self), Travel/Accommodation/Expenses: Merck; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Takeda; Roche; Advisory/Consultancy: AstraZeneca; MSD; BI. A. Charpidou: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AZ; Honoraria (self), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: BMS; Honoraria (self), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy: BI; Honoraria (self): MSD. A. Araújo: Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Eli Lilly; BMS; MSD; Roche; Sanofi; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): Astellas; Janssen; Advisory/Consultancy: Hospira; BMS; Pfizer; Clovis; BI; Takeda; Research grant/Funding (self): Pharmamar. K. Cuppens: Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; MSD; AZ; BI; Roche; Travel/Accommodation/Expenses: Pfizer; Research grant/Funding (self): Belgian Respiratory Society. O.T. Brustugun: Honoraria (self), Honoraria (institution), Research grant/Funding (institution), Travel/Accommodation/Expenses: AZ; Honoraria (self), Honoraria (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: BI; Honoraria (self), Travel/Accommodation/Expenses: Eli Lilly; Honoraria (self), Honoraria (institution), Travel/Accommodation/Expenses: MSD; BMS; Takeda; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (institution): GSK. M. Rajer: Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony: AZ; Roche; BMS; MSD; Lilly; Amgen; Travel/Accommodation/Expenses, Full/Part-time employment: Institute Of Oncology Ljublijana. M. Jakopovic: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; AZ; BI; MSD; Novartis; Pfizer. M.V. Marinca: Honoraria (self), Travel/Accommodation/Expenses: Merck; Astellas; Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: BMS; Honoraria (self): Accord; Amgen; Angelini; Eli Lilly; Johnson and Johnson; Sandoz; MSD; Solacium; BI; Honoraria (self), Advisory/Consultancy: AZ; Novartis; Ispen; Roche; Egis; Full/Part-time employment: Medical Oncology (IRO Iasi), Grigore T. Popa University of Medicine & Pharmacy, Iasi, Romania; Non-remunerated activity/ies: Comission For Treatment In Foriegn Countries. A. Pluzanski: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: BI; Pfizer; BMS; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AZ; Speaker Bureau/Expert testimony: MSD.